Decheng Capital LLC 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Decheng Capital LLC disclosed 26 US equity positions worth $422.2m in its Q3 2024 13F filing. The largest position was CGON at 49.0% of the reported book, followed by NUVB and PHAT.
What did Decheng Capital LLC own in Q3 2024? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | Healthcare | 49.0% | $206.7m | 5,478,810 | – | |
| 2 | NUVB Nuvation Bio Inc. | Healthcare | 14.1% | $59.4m | 25,954,439 | – | |
| 3 | PHAT PHATHOM PHARMACEUTICALS INC | 5.4% | $22.6m | 1,250,000 | – | ||
| 4 | RCUS Arcus Biosciences, Inc | Healthcare | 3.1% | $13.3m | 869,790 | – | |
| 5 | KRYS KRYSTAL BIOTECH INC | Healthcare | 3.1% | $13.1m | 71,772 | – | |
| 6 | ILMN Illumnia, Inc. | Healthcare | 2.9% | $12.4m | 94,767 | – | |
| 7 | ZNTL Zentalis Pharmaceuticals Inc. | Healthcare | 2.7% | $11.4m | 3,108,095 | – | |
| 8 | BYSI BeyondSpring Inc. | 2.7% | $11.4m | 4,958,143 | – | ||
| 9 | NEWAMSTERDAM PHARMA CO NV | 2.3% | $9.8m | 590,000 | – | ||
| 10 | MERUS NV | 2.2% | $9.4m | 189,098 | – | ||
| 11 | MOONLAKE IMMUNOTHERAPEUTICS | 2.0% | $8.4m | 166,600 | – | ||
| 12 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 1.9% | $8.1m | 157,958 | – | ||
| 13 | LEGN LEGEND BIOTECH CORP-ADR | Healthcare | 1.3% | $5.3m | 108,558 | – | |
| 14 | CYTK CYTOKINETICS INC | Healthcare | 1.2% | $5.0m | 94,043 | – | |
| 15 | AURA Aura Biosciences, Inc. | 1.1% | $4.6m | 515,555 | – | ||
| 16 | WGS GeneDx Holdings Corp. | Healthcare | 1.0% | $4.4m | 103,604 | – | |
| 17 | FDMT 4D MOLECULAR THERAPEUTICS IN | 1.0% | $4.3m | 397,835 | – | ||
| 18 | EQ Equillium Inc. | 0.9% | $3.7m | 4,447,308 | – | ||
| 19 | VERA VERA THERAPEUTICS INC | Healthcare | 0.7% | $3.1m | 69,767 | – | |
| 20 | LONGBOARD PHARMACEUTICALS IN | 0.4% | $1.9m | 56,350 | – | ||
| 21 | ACLXGBX ARCELLX INC | 0.4% | $1.8m | 21,177 | – | ||
| 22 | PYXS Pyxis Oncology, Inc (formerly Apexigen) | 0.3% | $1.2m | 326,810 | – | ||
| 23 | ATRC AtriCure Inc. | Healthcare | 0.2% | $751.4k | 26,797 | – | |
| 24 | GRAL GRAIL INC | 0.0% | $133.3k | 9,684 | – | ||
| 25 | RVMD REVOLUTION MEDICINES INC(NSM) | Healthcare | 0.0% | $90.7k | 2,000 | – | |
| 26 | Nuvation Bio Inc. | 0.0% | $63.2k | 646,057 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.